Lung Cancer Journal
@lungcajournal
Journal on clinical, translational & basic science of lung & chest malignancies #LCSM. Affiliated with @myESMO, @BTOGORG, @etop_ibcsg and ILCCO
ID: 1356275864430915589
http://www.lungcancerjournal.info 01-02-2021 16:19:25
154 Tweet
1,1K Followers
143 Following
🆕🗞️Out in the Lung Cancer Journal an excellent review investigating *Primary endpoints to assess the efficacy of novel therapeutic approaches in EGFR-mutated, surgically resectable NSCLC #LCSM lungcancerjournal.info/article/S0169-…
🚨just out in Lung Cancer Journal MET Alterations in Advanced NSCLC METCrusaders #LCSM lungcancerjournal.info/article/S0169-…
🚨just out in Lung Cancer Journal this important review lead by Martin Reck discussing the role of anti-angiogenic agents for the treatment of resistant NSCLC: rationale, recent updated and perspectives #LCSM 🔗 sciencedirect.com/science/articl…
🚨🆕 Just out in Lung Cancer Journal this review by Mariana Brandao et al, discussing “Systemic treatment & radiotherapy for pts with NSCLC & #HIV infection” #LCSM Find it here 🔗lungcancerjournal.info/article/S0169-…
See this month’s highlights from the ESMO - Eur. Oncology portfolio. Featured content from Annals of Oncology, ESMO Open, @ESMO_IOTECH, The Breast Online, Lung Cancer Journal, Cancer Treatment Reviews and Clinical Lymphoma Myeloma and Leukemia spkl.io/60114dyyV
🆕Just out in Lung Cancer Journal this interesting editorial by Jarushka Naidoo & . Francesco Cortiula discussing the role of neoadjuvant Osimertinib in resectable NSCLC, harbouring EGFR mutations #LCSM Here the link: lungcancerjournal.info/article/S0169-…
💡#LCSM a new review by Patrick Forde and colleagues, not to be missed!! Neoadjuvant immunotherapy in NSCLC!!! 🚨 lungcancerjournal.info/action/consume…
Happy to see our work on KL-6/MUC1 in pleural meso now out in Lung Cancer Journal: ➤ KL-6 lvls in pleural eff were diagnostic in 2 indep cohorts of pts with pleural meso. ➤⬆️KL-6 lvls and ⬆️MUC1 mRNA expression were associated with⬆️patient outcome. 👉lungcancerjournal.info/article/S0169-…
See this month’s highlights from the ESMO - Eur. Oncology portfolio. Featured content from Annals of Oncology, ESMO Open, @ESMO_IOTECH, The Breast Online, Lung Cancer Journal, Cancer Treatment Reviews and Clinical Lymphoma Myeloma and Leukemia spkl.io/60134dyVR
Outcomes with chemo-immunotherapy by #KRAS, STK11, and KEAP1 across PDL1 strata Lung Cancer Journal. KRAS mt enriched in PDL1 high but KRAS with co-mutations in STK11 and KEAP1 enriched in PDL1 negative. Poor OS in KRAS mt with PDL1 0% driven by STK11/KEAP1. lungcancerjournal.info/article/S0169-…
🚨📝 A pragmatic guide for management of adverse events associated with lorlatinib Link here 👉lungcancerjournal.info/article/S0169-… #LCSM ALK Positive
Stephen V Liu, MD Lung Cancer Journal Disappointing results from LU17-19 study. Osimertinib's lack of response is a setback. We need better treatment options, especially for specific exon 20 insertion mutations